Alpesh Jethva, MD
Nephrology · Tyler, TXNPI 1679622567
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.2% of the total across 52 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $432 and has fallen 75.7% since, to $105 in 2025. That places this record below the midpoint for nephrology clinicians in TX, where the typical reported total is $1,420.
Across 52 payments — averaging $25.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$160
- Amgen$127
- Ardelyx, Inc.$126
- GSK$123
- Otsuka America Pharmaceutical, Inc.$117
- Fresenius USA Marketing, Inc.$110
- plus $585 from 13 others
What the payments were for
- Food & beverage$1,27094%
- Education$786%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 9 | $160 |
| Amgen | 5 | $127 |
| Ardelyx, Inc. | 2 | $126 |
| GSK | 3 | $123 |
| Otsuka America Pharmaceutical, Inc. | 5 | $117 |
| Fresenius USA Marketing, Inc. | 5 | $110 |
| Bard Peripheral Vascular, Inc. | 1 | $102 |
| Jazz Pharmaceuticals Inc. | 1 | $93 |
| Vifor Pharma, Inc. | 3 | $62 |
| Bayer | 3 | $62 |
| Travere Therapeutics, Inc. | 2 | $50 |
| Akebia Therapeutics Inc | 3 | $46 |
| Calliditas Therapeutics US Inc. | 2 | $39 |
| Philips North America LLC | 2 | $36 |
| Novartis | 1 | $25 |
| Argon Medical Devices, Inc. | 2 | $24 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
| Cook Medical LLC | 1 | $15 |
| Lemaitre Vascular, Inc. | 1 | $14 |
How this compares
$1,348 in reported general payments places this provider in the 45th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 16 | $45,910 |
| AuryxiaFerric Citrate | 17 | $37,930 |
| Sevelamer Carbonate | 145 | $14,252 |
| FarxigaDapagliflozin Propanediol | 15 | $9,836 |
| Cyclosporine ModifiedCyclosporine, Modified | 12 | $2,253 |
| Calcium Acetate | 12 | $1,465 |
| Nifedipine ErNifedipine | 27 | $1,117 |
| Bumetanide | 15 | $911 |
| Calcitriol | 47 | $618 |
| Midodrine Hcl | 13 | $400 |
| Lisinopril | 62 | $380 |
| Potassium Chloride | 20 | $363 |
| Amlodipine Besylate | 49 | $270 |
| Omeprazole | 19 | $264 |
| Losartan Potassium | 41 | $244 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $110 | $45,91016 claims |
| Akebia Therapeutics IncAuryxia | $46 | $37,93017 claims |
| AstraZenecaFarxiga | $160 | $9,83615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,070 nephrology providers in Texas.
Other nephrology in Tyler
- Abdul AbdellatifWebster$2.1M
- German HernandezEl Paso$1.3M
- Ankit MehtaDallas$1.1M
- Biff PalmerDallas$867K
- Gates ColbertDallas$828K
- Sreedhar MandayamHouston$752K
- Luis VelezSan Antonio$505K
- Anand ReddyOdessa$469K
- Christopher KwohHouston$467K
- Wolfgang WinkelmayerHouston$462K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.